LIVIMMUNE
Live / Applied — Third extension granted (statement of use) (as of 05 Feb 2026)
What this means for you
Not registered yet, but its 03 Aug 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98115520
- Mark type
- Stylized text
- Filed
- 03 Aug 2023
- Published for opposition
- 11 Jun 2024
- Attorney of record
- Jared M. Barrett
Goods and services
- Class 005 — Pharmaceuticals: Therapeutic preparations, namely, therapeutic preparations for the treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19, and therapeutic preparations for the prevention of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; therapeutic preparations, namely, antibodies for use in targeting the CCR5 cell receptor
- Class 042 — Scientific and technological services: Scientific research consulting services, namely, scientific research consulting services in the field of immunology, and scientific research consulting services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; medical research services, and medical research services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; medical research services in the field of antibodies for use in targeting the CCR5 cell receptor
- Class 044 — Medical, beauty and agricultural services: Providing health and medical information, and providing health and medical information in the nature of providing a website featuring information in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; providing a website featuring medical information; providing a website featuring medical information in the field of antibodies for use in targeting the CCR5 cell receptor; medical analysis services, namely, medical analysis services in the field of antibodies for use in targeting the CCR5 cell receptor, and medical analysis services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19
Owner
- CytoDyn Inc., Vancouver, WA, US
- CytoDyn Inc., Vancouver, WA, US
Prosecution history
- 05 Feb 2026 — SOU EXTENSION 3 GRANTED
- 05 Feb 2026 — SOU EXTENSION 3 FILED
- 05 Feb 2026 — SOU TEAS EXTENSION RECEIVED
- 07 Aug 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 06 Aug 2025 — SOU EXTENSION 2 GRANTED
- 06 Aug 2025 — SOU EXTENSION 2 FILED
- 06 Aug 2025 — SOU TEAS EXTENSION RECEIVED
- 06 Feb 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 06 Feb 2025 — SOU EXTENSION 1 GRANTED
- 05 Feb 2025 — SOU EXTENSION 1 FILED
- 05 Feb 2025 — SOU TEAS EXTENSION RECEIVED
- 06 Aug 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 11 Jun 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 11 Jun 2024 — PUBLISHED FOR OPPOSITION
- 22 May 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED